Lotte Steuten
Lotte is a health economist by training and primarily interested in health technology assessment and decision analytic modelling of health innovations.
Alongside her position at OHE, Lotte is a Visiting Honorary Professor at City University of London, a member of the ISPOR Board of Directors and associate editor at Value in Health. She has published >100 peer–reviewed papers.
Lotte’s current research interests include applied health economics, health policy and market access. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new interventions across their lifecycle, and novel approaches to efficiently building the evidence for these.
Publications and Insights
- Publication: Taking STRIDES: The value of diagnostics against AMR
- Publication: Understanding the Full Value of Long-Acting Therapies: less is more?
- Publication: Analysing Global Immunisation Expenditure
- Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
- Publication: Employer Costs from Respiratory Infections
- Insight: R&D for new drugs to tackle AMR is a high-return investment for all EU member states
- Bulletin: Overcoming combination therapy challenges
- Publication: Unlocking the Value of Combination Therapies
- Insight: Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Publication: Developing a Conceptual Framework of Healthcare System Pressure
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Publication: Capturing the Broader Value of Antibiotics
- Insight: OHE’s AMR consultation response
- Bulletin: The power of better diagnostics
- Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
- Insight: Around The World in HTAs: The Netherlands – 5 Routes for New Tech
- Publication: A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Insight: Combination Therapies: A Step Forward to the Value Attribution Problem
- Publication: Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
- Insight: The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
- Insight: The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
- Insight: The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
- Insight: The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
- Publication: Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
- Insight: International Women’s Day: Why We #Choosetochallenge
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
- Publication: The Value of Vaccines in Maintaining Health System Capacity in England
- Publication: Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
- Publication: Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
- Publication: Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
- Publication: The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
- Publication: Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
- Publication: The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective